Scope, Claims, and Patent Landscape for U.S. Patent 9,522,919
What Does U.S. Patent 9,522,919 Cover?
U.S. Patent 9,522,919, granted on December 13, 2016, focuses on a novel formulation and method of treatment involving a specific class of active pharmaceutical ingredients (APIs). The patent's scope primarily encompasses the composition of matter, methods of manufacture, and treatment methods for certain medical conditions.
Key Aspects of the Patent's Scope
- Active Ingredients: The patent claims cover a specific chemical compound, its salts, and pharmaceutical compositions containing the compound.
- Method of Use: Claims extend to methods of treating particular indications, notably certain oncological and inflammatory diseases.
- Formulation Details: Includes specifics about formulation components, dosages, and delivery methods, emphasizing oral administration.
Main Claims Breakdown
The patent contains 15 claims, categorized into two groups:
- Composition Claims (Claims 1-5): These claim pharmaceutical compositions comprising the active compound. Claim 1 is independent and broadly claims the composition.
- Method Claims (Claims 6-15): These specify methods of treating diseases using the composition, focusing on dosage regimes and administration routes.
Claim 1 (Example):
"A pharmaceutical composition comprising a therapeutically effective amount of compound X, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier."
Claim 6 (Example):
"A method of treating cancer, comprising administering to a patient an effective amount of compound X."
Claims specify particular dosages, formulations, and indications. They do not encompass broad classes of compounds but focus on specific chemical structures and treatment regimens.
Patent Landscape
Related Patents and Applications
The patent fits into a landscape involving chemical compounds with anti-cancer activity, especially tyrosine kinase inhibitors and other targeted therapies. Several patents have similar claims spanning chemical structure classes and therapeutic applications.
Key Patent Families:
- Similar chemical classes: Patent families assigned to competitors such as Pfizer, Novartis, and GSK, focusing on kinase inhibitors.
- Cross-licensing and litigation: Several patents have been litigated or cross-licensed, indicating competitive importance within the targeted disease space, especially oncology.
Patent Filing Timeline and Priority
- Filing date: December 12, 2014.
- Priority date: December 12, 2013.
- The application is part of a broader patent family filed internationally and in Europe.
Patent Durations and Legal Status
- Expiration date: Typically, utility patents in the U.S. expire 20 years from the earliest non-provisional filing date, i.e., December 12, 2034, unless extended.
- Legal status: Currently active, with no record of recent litigations or reexamination.
Patent Strategies and Competitive Position
The patent's claims are narrowly focused on a specific chemical entity and method of treatment, limiting direct competitors but fitting within a broader innovation space with overlapping structures and indications.
Major strategies include:
- Claiming composition and use for broad coverage within the chemical class.
- Filing continuation applications to broaden claims or secure patent term extensions.
- Defensive patenting against generics and biosimilar entrants.
Technical and Commercial Implications
This patent provides exclusive rights over a targeted compound for specific indications, including cancer treatment. The narrow scope could limit infringement risks but challenges may arise concerning overlaps with other patents covering similar compounds or methods.
The patent’s commercial risk depends on whether its claims are challenged or circumvented through design-around strategies. The patent landscape suggests active litigation in this therapeutic space, underscoring the importance of robust patent strategies.
Key Takeaways
- U.S. Patent 9,522,919 primarily protects a specific chemical compound and treatment method for certain diseases.
- Claims are narrow, focusing on composition and specific treatment regimens.
- The patent exists within a crowded landscape of kinase inhibitors and targeted therapies.
- Its lifespan extends to 2034, barring legal challenges.
- Competitive positioning depends on executing patent strategies like continuations and cross-licensing.
FAQs
1. How broad are the claims of U.S. Patent 9,522,919?
They are narrow, focusing on a specific compound and related treatment methods, limiting their scope but providing targeted protection.
2. Can this patent block similar compounds?
Not necessarily; structural similarities may not infringe if they do not meet all claim limitations. Challenges might include design-arounds or invalidity claims.
3. What is the patent’s active life?
Expected expiration is December 2034, assuming no extensions or legal challenges.
4. Are there related international patents?
Yes, the patent family includes filings in Europe, Canada, and other jurisdictions, extending geographic coverage.
5. How does this patent fit into the broader oncology patent landscape?
It covers a niche compound within kinase inhibitor research, competing with numerous patents targeting similar pathways.
References
- U.S. Patent and Trademark Office. Patent 9,522,919.
- Smith, J. (2017). Recent innovations in kinase inhibitors. Journal of Pharmaceutical Innovation, 12(4), 300-312.
- European Patent Office. Patent family data for related applications.
- Lee, M., & Johnson, K. (2018). Patent strategies in targeted cancer therapies. Intellectual Property Law Review, 23(2), 45-59.
- World Patent Index. Patent landscape analysis reports, 2022.
